A Prospective Cohort Study Evaluating the Utility of Artificial Intelligence-Assisted Non-Contrast Computed Tomography for Multi-Cancer Screening in Asymptomatic Individuals Undergoing Routine Health Examinations

Status: Recruiting
Location: See location...
Intervention Type: Diagnostic test
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

Cancer poses a major public health challenge in China. Early detection can improve treatment outcomes and survival rates. In this study, we will conduct a large-scale, prospective, multi-center cohort study to evaluate the utility of AI-assisted non-contrast CT for multi-cancer screening. The study aims to enroll 1 million asymptomatic participants undergoing routine health examinations, using an AI imaging model based on non-contrast CT to detect seven cancers such as lung, liver, gastric, colorectal, esophageal, pancreatic, and breast cancers. Positive cases will be required to be referred to Shanghai Changhai Hospital for further imaging and care based on National Comprehensive Cancer Network (NCCN) and American College of Radiology (ACR) guidelines. The goal is to assess the AI model's diagnostic performance for seven cancer types, especially for early-stage, resectable tumors.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: t
View:

• Subject is able and willing to provide informed consent and sign an informed consent form.

• Subject has undergone an abdominal or chest non-contrast CT scan.

Locations
Other Locations
China
Changhai Hospital
RECRUITING
Shanghai
Contact Information
Primary
Wang Beilei, M.D.
lilly_wang@126.com
86-13774238083
Backup
Guo Shiwei, M.D.
gestwa@163.com
86-18621500666
Time Frame
Start Date: 2024-10-07
Estimated Completion Date: 2027-10-07
Participants
Target number of participants: 1000000
Treatments
Experimental: Health Examination Cohort
Asymptomatic participants in routine health examinations receive abdominal or chest non-contrast CT scans, categorized as follows:~1. Meinian cohort~2. Changhai cohort
Sponsors
Leads: Guo ShiWei

This content was sourced from clinicaltrials.gov